Home>Topics>Stocks>Mead Johnson Nutrition Company

Mead Johnson Nutrition Company MJN

  1. All
  2. Commentary
  3. Stock Reports
  4. Fund Reports
  5. ETF Reports
  6. Headlines
    1. Mead raises guidance after Q2 results

      Headlines

      Tue, 22 Jul 2014

      Mead Johnson Nutrition Company (NYSE: MJN ) Q2 results : Net Sales: $1,111.1M (+5.3%); R&D Expense: $26.7M (+7.7%); SG&A Expense: $416.9M

    2. Mead Johnson Nutrition misses by $0.01, beats on revenue

      Headlines

      Tue, 22 Jul 2014

      Mead Johnson Nutrition (NYSE: MJN ): Q2 EPS of $0.88 misses by $0.01 . Revenue of $1.11B (+4.7% Y/Y) beats by $10M . Press Release Post your comment!

    3. Notable earnings before Tuesday's open

      Headlines

      Mon, 21 Jul 2014

      CNC , COL , CS , CSL , DD , DFRG , DPZ , EDU , EXAS , FMER , GCI , HOG , HUB.B , IR , KMB , KO , LMT , LPT , LXK , MCD , MJN , MO , MOSY , NEOG , OMC , PII , PLD , RESI , RF , SAH , SBNY , SILC , SNV , STT , TRV , UTX , VZ , WAT , WRLD Post your comment

    4. PJP PowerShares Dynamic Pharmaceuticals ETF Analysis, Report, Research, 5 Star Rating – Morningstar

      ETF Reports

      Mon, 5 May 2014

      diagnostics division, point-of-care diagnostics division), Pfizer (Zoetis ZTS), and Bristol-Myers Squibb BMY (Mead Johnson MJN ). Other deals have been due to cost-cutting potential or firms exiting areas where they lacked critical mass. The sector

    5. IHE iShares US Pharmaceuticals ETF Analysis, Report, Research, 5 Star Rating – Morningstar

      ETF Reports

      Mon, 5 May 2014

      diagnostics division, point-of-care diagnostics division), Pfizer (Zoetis ZTS), and Bristol-Myers Squibb BMY (Mead Johnson MJN ). Other deals have been due to cost-cutting potential or firms exiting areas where they lacked critical mass. The sector

    6. XPH SPDR S&P Pharmaceuticals ETF ETF Analysis, Report, Research, 5 Star Rating – Morningstar

      ETF Reports

      Mon, 5 May 2014

      diagnostics division, point-of-care diagnostics division), Pfizer (Zoetis ZTS), and Bristol-Myers Squibb BMY (Mead Johnson MJN ). Other deals have been due to cost-cutting potential or firms exiting areas where they lacked critical mass. The sector

    7. From Barron’s, November 25, 2013 (Part 1)

      Commentary

      Sat, 23 Nov 2013

      policy of allowing up to 2 babies if one parent is the only child may boost baby formula makers ; recommended are selling puts on MJN . Buying ^ VIX calls has been a losing trade this year, but “burnt children” [borrowing from Oscar Wilde ] continue to

    8. Mead Johnson Shares Pop as Firm Maintains Fiscal 2013 Guidance, Despite Price Decreases in China

      Commentary

      Thu, 25 Jul 2013

      Mead Johnson MJN reported second-quarter results (roughly in line with our expectations) and reiterated its 2013 adjusted earnings guidance

    9. From Barron’s, July 22, 2013 (Part 2)

      Commentary

      Sat, 20 Jul 2013

      and China has an massive influence on commodity prices [ and related companies ]. In the consumer-staple area, the lag in MJN , WMT is due to the China factor . This can extend to materials, industrials and IT where China-related lag may develop for

    10. Mead Johnson Lowering Prices on Some China Products by 7%-15%; Maintaining Fair Value Estimate

      Commentary

      Wed, 10 Jul 2013

      Mead Johnson MJN has announced its intentions to decrease the ex-factory price of its main products sold in China by 7%-15%, echoing changes

    « Prev1234Next »
    Content Partners